Antares pharma reports q1 loss per share of $0.01

Antares pharma reports first quarter 2020 operating and financial results.q1 loss per share $0.01.q1 revenue $33.1 million versus refinitiv ibes estimate of $31.9 million.q1 earnings per share estimate $-0.00 -- refinitiv ibes data.sales of xyosted and otrexup generated revenue of $12.6 million for quarter, up 163%.at march 31, 2020, cash, cash equivalents and short term investments were $50.3 million.suspending previously announced 2020 net revenue guidance..
ATRS Ratings Summary
ATRS Quant Ranking